We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Quanterix Acquires Magnetic Bead Tech Firm Emission

By LabMedica International staff writers
Posted on 18 Dec 2024
Print article
Image: The CUBE mid-plex platform is up to 100X more sensitive than legacy systems (Photo courtesy of EMISSION)
Image: The CUBE mid-plex platform is up to 100X more sensitive than legacy systems (Photo courtesy of EMISSION)

Quanterix Corporation (Billerica, MA, USA), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, has acquired EMISSION iNC (Georgetown, TX, USA), expanding its technology capabilities through vertical integration of proprietary bead technology.

Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs made possible through its unparalleled sensitivity and flexibility. The company’s Simoa technology has delivered the gold standard for earlier biomarker detection in blood, serum, or plasma, with the ability to quantify proteins far lower than the Limit of Quantification (LoQ) of conventional analog methods. EMISSION manufactures large-scale, highly uniform dye-encapsulating magnetic beads designed for low and mid-plex assays and a mid-plex platform that reads its proprietary beads. Vertically integrating EMISSION will allow Quanterix to secure the use of EMISSION’s highly controlled beads in Quanterix’s next-generation platform and to develop a new multi-plex segment targeting third parties.

“As we expand our technology stack toward higher multi-plex and multi-omic capabilities, it is imperative we control core components,” said Masoud Toloue, Chief Executive Officer of Quanterix. “EMISSION’s proprietary bead technology has already been validated on our upcoming new Simoa platform and will enable us to provide OEM beads to other non-Quanterix platforms. We look forward to welcoming EMISSION’s innovations and colleagues to the Quanterix team.”

“EMISSION was built on our high-quality bead technology and we believe that better beads and ultimately better multi-plex assays should be within everyone’s reach,” added Van Chandler, CEO of EMISSION. “Having known and worked with the Quanterix team for years, we are excited to join forces, as we support the upcoming Simoa platform and a shared vision for expanding the technology’s reach to all labs.”

Related Links:
Quanterix Corporation
EMISSION iNC

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
New
Treponema Pallidum Test
ZEUS IFA Fluorescent Treponemal Antibody-Absorption (FTA-ABS) Test System
New
Orienta Tsutsugamushi Test
STANDARD Q Tsutsugamushi IgM/IgG

Print article

Channels

Molecular Diagnostics

view channel
Image: Umbilical cord blood biomarkers may improve preterm infant care (Photo courtesy of Shutterstock)

Umbilical Cord Blood Test Could Identify Preterm Infants at Risk for Medical Complications

Advancements in medical technology and neonatology have significantly improved the care of prematurely born infants. However, these infants still face heightened risks for medical complications, such as... Read more

Immunology

view channel

3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response

Tumor heterogeneity presents a major obstacle in the development and treatment of cancer therapies, as patients' responses to the same drug can differ, and the timing of treatment significantly influences prognosis. Consequently, technologies that predict the effectiveness of anticancer treatments are essential in minimizing... Read more

Microbiology

view channel
Image: The Cytovale System isolates, images, and analyzes cells (Photo courtesy of Cytovale)

Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application

Sepsis is the leading cause of death and the most expensive condition treated in U.S. hospitals. The risk of death from sepsis increases by up to 8% for each hour that treatment is delayed, making early... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.